47
Participants
Start Date
July 27, 2015
Primary Completion Date
July 7, 2020
Study Completion Date
July 7, 2020
CC-122
CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
Ibrutinib
Obinutuzumab
Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
Allgemeines Krankenhaus Wien, Vienna
University Hospital of Salzburg St Johanns Spital, Salzburg
University Hospital Innsbruck, Innsbruck
Weill Cornell Medical College Dr. Feldman's Office, New York
Istituto Clinico Humanitas, Rozzano (MI)
Fondazione Centro San Raffaele del Monte Tabor, Milan
Ospedale Niguarda Milano, Milan
University of Schleswig-Holstein, Kiel
Fundacion Jimenez Daaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario de Salamanca, Salamanca
The West Clinic, Memphis
Hospital Universitario Virgen Del Rocio, Seville
Arcispedale Santa Maria Nuova, Reggio Emilia
Ohio State University Medical CenterJames Cancer Hospital, Columbus
Universitaetsklinikum EssenInnere Klinik und Poliklinik, Essen
Universitat zu Koln, Cologne
MD Anderson Cancer Center The University of Texas, Houston
University of California San Diego, La Jolla
Universitatsklinikum Würzburg, Würzburg
Fred Hutchinson Cancer Research Center, Seattle
Dana Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Hospital Universitario Vall D hebron, Barcelona
Lead Sponsor
Celgene
INDUSTRY